Pharmacological Tools: Doses, Routes, and Uses of Common Drug

Download as pdf or txt
Download as pdf or txt
You are on page 1of 1

4

ADVANCED CARDIAC
LIFE SUPPORT

PHARMACOLOGICAL TOOLS
Use of any of the ALCS medication in Table 1 should be done within your scope of practice and after
thorough study of the actions and side effects. This table only provides a brief reminder for those who
are already knowledgeable in the use of these medications. Moreover, Table 1 contains only adult
doses, indications, and routes of administration for the most common ACLS drugs.

Doses, Routes, and Uses of Common Drug

DRUG MAIN ACLS USE DOSE/ROUTE NOTES

• Rapid IV push close to the hub, followed by a


• Narrow PSVT/SVT saline bolus
• Wide QRS tachycardia, • 6 mg IV bolus, may repeat with 12 mg in
Adenosine 1 to 2 min.
• Continuous cardiac monitoring during
avoid adenosine in administration
irregular wide QRS
• Causes flushing and chest heaviness

• Anticipate hypotension, bradycardia, and


• VF/pulseless VT gastrointestinal toxicity
• VT with pulse • VF/VT: 300 mg dilute in 20 to 30 mL, may • Continuous cardiac monitoring
Amiodarone repeat 150 mg in 3 to 5 min • Very long half-life (up to 40 days)
• Tachycardia
rate control • Do not use in 2nd or 3rd-degree heart block
• Do not administer via the ET tube route

• Symptomatic • 0.5 mg IV/IO every 3 to 5 minutes • Cardiac and BP monitoring


bradycardia • Max dose: 3 mg • Do not use in glaucoma or
Atropine tachyarrhythmias
• Specific toxins/overdose • Minimum dose 0.5 mg
• 2 to 4 mg IV/IO may be needed
(e.g. organophosphates)

• Shock/CHF
• 2 to 20 mcg/kg/min • Fluid resuscitation first
Dopamine • Symptomatic
• Titrate to desired blood pressure • Cardiac and BP monitoring
bradycardia

• Initial: 1.0 mg (1:10000) IV or 2 to 2.5 mg


(1:1000)
• Cardiac Arrest
• Maintain: 0.1 to 0.5 mcg/kg/min Titrate to
desire blood pressure • Continuous cardiac monitoring
• Note: Distinguish between 1:1000 and 1:10000
Epinephrine • 0.3-0.5 mg IM concentrations
• Anaphylaxis
• Repeat every five minutes as needed • Give via central line when possible

• Symptomatic • 2 to 10 mcg/min infusion


bradycardia/Shock • Titrate to response

• Initial: 1 to 1.5 mg/kg IV loading


• Cardiac Arrest (VF/VT) • Second: Half of first dose in 5 to 10 min
Lidocaine • Maintain: 1 to 4 mg/min
• Cardiac and BP monitoring
(Lidocaine is • Rapid bolus can cause hypotension and
recommended when
Amiodarone is not bradycardia
• Initial: 0.5 to 1.5 mg/kg IV
available) • Wide complex • Use with caution in renal failure
• Second: Half of first dose in 5 to 10 min
tachycardia with pulse
• Maintain: 1 to 4 mg/min

• Cardiac arrest/ • Cardiac Arrest: 1 to 2 gm diluted in 10 mL • Cardiac and BP monitoring


Pulseless torsades D5W IVP • Rapid bolus can cause hypotension and
bradycardia
Magnesium Sulfate
• If not cardiac arrest: 1 to 2 gm IV over 5 to 60 • Use with caution in renal failure
• Torsades de Pointes min
with pulse • Calcium chloride can reverse
• Maintain: 0.5 to 1 gm/hr IV hypermagnesemia

• 20 to 50 mg/min IV until rhythm improves, • Cardiac and BP monitoring


hypotension occurs, QRS widens by 50%
• Wide QRS tachycardia • Caution with acute MI
or MAX dose is given
Procainamide • Preferred for VT with • MAX dose: 17 mg/kg
• May reduce dose with renal failure
pulse (stable) • Do not give with amiodarone
• Drip: 1 to 2 gm in 250 to 500 mL at
1 to 4 mg/min • Do not use in prolonged QT or CHF

• Tachyarrhythmia
Table 1 Sotalol • Monomorphic VT • 100 mg (1.5 mg/kg) IV over 5 min • Do not use in prolonged QT
• 3rd line anti-arrhythmic

29 ACLS – Advanced Cardiac Life Support

You might also like